Toggle Health Problems and D

2 X better survival of digestive cancer if 2,000 IU of Vitamin D plus good VDBP gene – RCT Feb 2020

Effect of Vitamin D Supplementation on Survival of Digestive Tract Cancer Patients with Low Bioavailable 25-Hydroxyvitamin D levels: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Cancers 2020, 12(2), 347; https://doi.org/10.3390/cancers12020347 (registering DOI)


Items in both categories Colon Cancer and Vitamin D Binding Protein are listed here:

Vitamin D Binding Protein category listing has 174 items and the following introduction

Vitamin D Binding Protein (GC) gene can decrease the bio-available Vitamin D that can get to cells,

  • GC is not the only such gene - there are 3 others, all invisible to standard Vitamin D tests
  • The bio-available calculation does not notice the effect of GC, CYP27B1, CYP24A1, and VDR
  • The actual D getting to the cells is a function of measured D and all 4 genes
  • There is >2X increase in 8+ health problems if have poor VDBP (GC)
  • It appears that VDBP only blocks oral vitamin D,

VDBP is NOT directly detected by vitamin D blood tests
in Visio for 2023
click on chart for detials

 Download the PDF from VitaminDWiki

Mitsuyoshi Urashima 1,*,Mai Okuyama 1,Taisuke Akutsu 1,Hironori Ohdaira 2,Mutsumi Kaji 2 and Yutaka Suzuki 2

  • 1 Division of Molecular Epidemiology, Jikei University School of Medicine, 3-25-8, Nishi-Shimbashi, Minato-Ku, Tokyo 105-8461, Japan
  • 2 Department of Surgery, International University of Health and Welfare Hospital, 537-3 Iguchi, Nasushiobara, Tochigi 329-2763, Japan

Vitamin D has been shown to suppress the growth of cancer cells. Cancer cells are believed to take up bioavailable 25-hydroxyvitamin D (25OHD) (i.e., not bound to vitamin-D-binding protein (DBP)) more efficiently than DBP-bound 25(OH)D. Our aim was to use this bioavailable 25(OH)D, rather than total 25(OH)D, as a biomarker of vitamin D deficiency to investigate whether vitamin D supplementation improves the relapse-free survival (RFS) of patients with digestive tract cancer from the esophagus to the rectum by conducting a post hoc analysis of the AMATERASU trial (UMIN000001977). The bioavailable 25(OH)D levels were calculated via an equation using data of serum total 25(OH)D, albumin, and DBP levels, and DBP genotypes (rs7041 and rs4588). We estimated bioavailable 25(OH) levels in 355 patients.
In a subgroup of patients with low bioavailable 25(OH)D levels (<median) (n = 177), 5 year RFS was 77% in the vitamin D group vs. 58% in the placebo group (hazard ratio, 0.54; 95% confidence interval, 0.31–0.95; p = 0.03), whereas no significant difference was seen in a subgroup of patients with high bioavailable 25(OH)D levels (p for interaction = 0.046). We hypothesize that vitamin D supplementation may be effective in improving RFS among digestive tract cancer patients with low bioavailable 25(OH)D levels.

Created by admin. Last Modification: Tuesday February 4, 2020 17:56:38 GMT-0000 by admin. (Version 3)

Attached files

ID Name Comment Uploaded Size Downloads
13445 Bioavailable.jpg admin 04 Feb, 2020 17:49 23.50 Kb 365
13444 Risk of relapse.jpg admin 04 Feb, 2020 17:49 43.81 Kb 474
13443 AMATERASU RCT.pdf PDF 2020 admin 04 Feb, 2020 17:48 674.87 Kb 406